medigraphic.com
ISSN 1817-5996 (Electronic)

2015, Number S1

<< Back Next >>

Rev Cub de Reu 2015; 17 (S1)

Lom syndrome and neuropsychiatric manifestations of one patient with Lupus

Batún GJAJ, Hernández NÉ, Abud MC

Language: Spanish
References: 13
Page: 230-234
PDF size: 319.26 Kb.


ABSTRACT

Lom syndrome is the association between lupus and protein energy malnutrition lupus with high levels of autoantibodies. Neuropsychiatric lupus is the least understood and the most frequently systemic lupus erythematosus expression, a sign of bad prognosis and high mortality, the manifestations may arise before the disease develops and simulate signs of myelopathy, demyelination and behavioral disorders. We report the case of a patient with neuropsychiatric manifestations as systemic lupus erythematosus activity data and expression of Lom syndrome.


REFERENCES

  1. Lom-Orta H, Diaz-Jouanen E, Alarcon-Segovia D. Protein-caloric malnutrition and systemic lupus erythematosus. J Rheumatol. 1980;7(2):178-82.

  2. Popescu A, Kao A. Neuropsychiatric Systemic Lupus Erythematosus. Current Neuropharmacology. 2011;9:449-57.

  3. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1726-32.

  4. Raghavendra N, Govind B, Nanasaheb P, Nanasaheb M. Patil, Semeeran C. Psychosis in Patients with Systemic Lupus Erythematosus. Indian J Psychol Med. 2012;34(1):90-3.

  5. Ross DA, Cetas JS. Steroid psychosis: a review for neurosurgeons. J Neurooncol. 2012;109(3):439-47.

  6. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1507-9.

  7. Martins S, Buscatti I, Freire P, Cavalcante E, Salluma A, Campos L, et al. Kikuchi-Fujimoto disease prior to childhood-systemic lupus erythematosus diagnosis. rev bras reumatol. 2014;54(5):400-3.

  8. Kitsanou M, Andreopoulou E, Bai MD, Elisaf M, Drosos AA. Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus. Lupus. 2000;9:140-3.

  9. Mok C, To C, Ma K. Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus. Lupus. 2008;17(11):1018-22.

  10. Fregoso-Loyo H, Cabiedes J, Orozco-Narvaez A, Davila Maldonado L, Atisha Fregoso Y, Diamond B, et al. Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis. Plos One. 2008;3(10):3347-54.

  11. Díaz D, Correa N, Díaz M, Gutiérrez J, Fernández D. Compromiso del sistema nervioso central en el lupus eritematoso sistémico. rev colomb reumatol. 2015;22(1):16-30.

  12. Bertsias GK, Ioannidis JPA, Aringer M, Bollen E, Bombardieri S, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074-82.

  13. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620-25.




2020     |     www.medigraphic.com